ACGT 2017 Anniversary Gala

Dr. John Lahey, president of Quinnipiac University and an ACGT Board member since 2004.Alliance for Cancer Gene Therapy Anniversary Gala to Honor
Dr. John Lahey with the first Edward Netter Award for Business

ACGT’s Anniversary Gala will take place on Wednesday, April 19, 2017 at 6:30pm at The Harvard Club of New York City. Barbara Netter, ACGT’s honorary chairman of the Board and co-founder, will present the first-ever Edward Netter Award for Business to Dr. John Lahey, president of Quinnipiac University and an ACGT Board member since 2004. Dr. Lahey embodies the qualities prized by ACGT co-founder Edward Netter: intellect, creativity, tenacity, curiosity and compassion. He is the eighth President of Quinnipiac University, a private university located in Hamden, Connecticut. Upon his arrival at Quinnipiac in March of 1987, Dr. Lahey initiated a strategic planning process that has resulted in the growth of student enrollment from 2,000 to nearly 10,000 students. He also expanded Quinnipiac from a college to a university, which now offers more than 100 programs in its nine schools and colleges: Arts and Sciences, Business, Communications, Education, Engineering, Health Sciences, Law, Medicine and Nursing.

ACGT research fellow, Dr. Robert Vonderheide of the University of Pennsylvania, will speak about his current work in immunotherapy and gene therapy that is targeting pancreatic cancer and solid tumors. ACGT funded Dr. Vonderheide’s early research work in immunotherapy.

Doug Olson of Tinicum Township, PA will share the details of his experience as “patient #2” in the first CAR T 19 immunotherapy trial in September 2010 at the University of Pennsylvania. The treatment for the trial was developed by ACGT research fellow, Dr. Carl June. Doug was diagnosed with chronic lymphocytic leukemia (CLL) in July 1996 and has remained in remission since completing the trial.

“This Gala offers the opportunity to celebrate the successes of ACGT research fellows and honor those who make it all possible,” said John Walter, CEO and president of ACGT. “With our donors’ support, ACGT has been able to be a part of finding and funding some of the most exciting cancer treatment breakthroughs, several of which we anticipate coming to market this year.”

Tickets are $750 each and can be purchased online below or by mailing a check made out to ACGT to the following address: ACGT, 96 Cummings Point Rd, Stamford, CT 06902.

Sponsorships are available. For more information, contact Barbara Gallagher at bgallagher@acgtfoundation.org or 203.358.5055.